Role of once-daily tadalafil in men with concomitant erectile dysfunction and symptomatic benign prostatic hyperplasia: A prospective randomized placebo-controlled study
Background: Majority of men over age 50 are sexually active and sex is an important part of overall quality of life. Both benign prostatic hyperplasia (BPH) with lower urinary tract symptoms-BPH (BPH-LUTS) and erectile dysfunction (ED) are often found in this age group simultaneously. Pathophysiolog...
Main Authors: | Sunder Goyal, Snigdha Goyal, Isha Saini |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2015-01-01
|
Series: | Indian Journal of Health Sciences and Biomedical Research KLEU |
Subjects: | |
Online Access: | http://www.ijournalhs.org/article.asp?issn=2542-6214;year=2015;volume=8;issue=1;spage=56;epage=59;aulast=Goyal |
Similar Items
-
New approaches to management of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia
by: S. I. Gamidov, et al.
Published: (2019-10-01) -
Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication
by: Ali Hamidi Madani, et al.
Published: (2012-02-01) -
Effectiveness and safety of Tadalafil-SZ (NJSC “Northern Star”) at 5 mg / day in patients with symptoms of voiding dysfunction due to prostatic hyperplasia
by: L. G. Spivak, et al.
Published: (2019-10-01) -
Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial
by: Arcangelo Sebastianelli, et al.
Published: (2019-07-01) -
Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations
by: Lee LK, et al.
Published: (2016-07-01)